787
Participants
Start Date
December 21, 2009
Primary Completion Date
July 1, 2012
Study Completion Date
August 23, 2017
obinutuzumab
1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
rituximab
375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
chlorambucil
Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Auckland
Vienna
Vienna
Buenos Aires
Buenos Aires
Sofia
Rosario
St Leonards
Copenhagen
Sydney
Liverpool
Kogarah
Gosford
Vratsa
Bern
Melbourne
Frankston
Plovdiv
Basel
Woolloongabba
Greenslopes
Southport
Odense
Aarau
Adelaide
Kurralta Park
Pleven
Lucerne
Innsbruck
Chur
Vejle
Aarhus
Christchurch
Graz
Zurich
Aalborg
Sankt Gallen
Varna
Zagreb
Orbassano
Torino
Bangkok
Bangkok
Bangkok
Jerez de la Frontera
Cairo
Berlin
Marseille
Tallinn
Caen
A Coruña
Frankfurt (Oder)
Santiago de Compostela
Genova
Greifswald
Rostock
Donostia / San Sebastian
Hamburg
Hamburg
Aguascalientes
Milan
Milan
Hamburg
Baltimore
Hamburg
Hamburg
Hamburg
Jaén
Kiel
Oldenburg
Leer
Madrid
Madrid
Madrid
Madrid
Madrid
Madrid
Bremen
Bremen
Madrid
Bremen
Madrid
Málaga
Málaga
Murcia
Murcia
Hanover
Pamplona
Toulouse
Porta Westfalica
Lemgo
Detmold
Oviedo
Pessac
Montpellier
Las Palmas
Rennes
Salamanca
Tours
Göttingen
San Cristóbal de La Laguna
Santander
Magedburg
Khon Kaen
Seville
Modena
Nantes
Ferrara
Toledo
Essen
Essen
Toledo
Recklinghausen
Valencia
Valencia
Valencia
Valencia
Valencia
Gandia
Duisburg
Ahaus
Angers
Zaragoza
Frechen
Cologne
Cologne
Tartu
Reims
Eschweiler
Bonn
Waukesha
Trier
Green Bay
Vandœuvre-lès-Nancy
Mainz
Koblenz
Witten
Lüdenscheid
Lille
Hamm
Frankfurt am Main
Frankfurt
Chicago
Clermont-Ferrand
Monterrey
Rüsselsheim am Main
Saarbrücken
Homburg/Saar
Neunkirchen/Saar
Lebach
Worms
Kaiserslautern
Mannheim
Heidelberg
Lyon
Pierre-Bénite
Stuttgart
Sindelfingen
Le Mans
Tübingen
Wendlingen
Mutlangen
Esslingen am Neckar
Paris
Paris
Rouen
Karlsruhe
Villingen-Schwenningen
San Luis Potosí City
Freiburg im Breisgau
Loerrach
Culiacán
München
München
München
München
München
Weilheim
Hermosillo
Landshut
Poitiers
Cosenza
Kempten
Ravensburg
Ulm
Nuremberg
Erlangen
Erlangen
Ansbach
San Diego
Amberg
Bobigny
Regensburg
Regensburg
Créteil
Bamberg
Kronach
Würzburg
Messina
Rostov-on-Don
Kazan'
Penza
Ufa
Târgu Mureş
Nizhny Novgorod
Perm
Buenos Aires
Buenos Aires
Buenos Aires
Buenos Aires
Goiânia
Belo Horizonte
Porto Alegre
Santo André
São Paulo
Calgary
Edmonton
Winnipeg
Halifax
Barrie
Ottawa
Montreal
Rimouski
Brno
Hradec Králové
Prague
Delitzsch
Dresden
Dresden
Giessen
Hong Kong
Cagliari
Roma
Roma
Roma
Terni
Delftzijl
Enschede
Leeuwarden
Nieuwegein
Bucharest
Bucharest
Bratislava
Manresa
Sabadell
Barcelona
Barcelona
Barcelona
Barcelona
Bournemouth
Cambridge
Canterbury
Cardiff
Cottingham
Edinburgh
Glasgow
Leicester
London
London
Nottingham
Sutton
Collaborators (1)
German CLL Study Group
OTHER
Genentech, Inc.
INDUSTRY
Hoffmann-La Roche
INDUSTRY